Menu

Rothwell Figg Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

Teva

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: Teva
  • Posted in:

    • Legal

    Genentech’s Carter ’213 Patent Asserted and Challenged

    By Spencer Johnson March 5, 2018 Comments are off

    In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...

    Read more

    Tagged with: BLA, Boehringer Ingelheim, BPCIA, Celltrion, District Court, Genentech, Herceptin®, IPR, Litigation, Mylan, Pfizer, Samsung Bioepsis, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents

    By Seth Cockrum January 16, 2018 Comments are off

    We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...

    Read more

    Tagged with: Biogen, Celltrion, Genentech, Herceptin®, IPR, News, PTAB, Rituxan®, Rituximab, Roche, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion and Teva File Declaratory Judgment Action Against Thirty–Eight Herceptin®-related Patents

    By Seth Cockrum January 15, 2018 Comments are off

    On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...

    Read more

    Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Two New Applications for Trastuzumab (Herceptin®) Biosimilars Pending at FDA

    By C. Nichole Gifford August 11, 2017 Comments are off

    Amgen and Allergan recently announced that they submitted a Biologics License Application (“BLA”) for ABP 980, a proposed biosimilar to...

    Read more

    Tagged with: Allergan, Amgen, Biocon, Celltrion, FDA, Genentech, Herceptin®, Hospira, Mylan, News, Pfizer, Regulatory, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion’s Application for Rituxan® (rituximab) Biosimilar Accepted by FDA

    By C. Nichole Gifford July 3, 2017 Comments are off

    Celltrion announced last week that its Biologics License Application (“BLA”) for CT-P10, a biosimilar to Biogen and Genentech’s...

    Read more

    Tagged with: Biogen, Celltrion, FDA, Genentech, News, Regulatory, Rituxan®, Rituximab, Teva

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Pfizer Challenges Genentech’s Carter ’213 Antibody Patent With Two New IPR Petitions

    By C. Nichole Gifford June 2, 2017 Comments are off

    On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, Hospira, IPR, Legal, Mylan, News, Pfizer, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Challenges Another Herceptin® Patent With Two New IPR Petitions

    By C. Nichole Gifford May 18, 2017 Comments are off

    Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Files Three IPR Petitions Against Two More Rituximab Patents

    By C. Nichole Gifford April 4, 2017 Comments are off

    On March 31, 2017, Celltrion, Inc. (“Celltrion”) filed three new petition for inter partes review (“IPR”) of two additional patents...

    Read more

    Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, News, PTAB, Rituxan®, Rituximab, Teva, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Targets Four More Herceptin® Patents in IPR Petitions

    By C. Nichole Gifford March 24, 2017 Comments are off

    On March 21, 2017, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent Nos....

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Pages

  • 1
  • 2
  • Next

Featured Posts

  • Litigation Spotlight Update: The Infliximab (Remicade®) Litigation

    February 5, 2018

  • Litigation Spotlight Update: The Epoetin alfa (Epogen®) Litigation

    August 2, 2017

  • Litigation Spotlight Update: The Saga Continues: The Infliximab (Remicade®) Litigation

    June 12, 2017

Sign Up for Updates


Don’t worry. We don’t spam.

Thank you for subscribing.

Already subscribed.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mabthera Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Knowledge Center
  • Events
  • Professionals

Connect

  • Connect with Us on LinkedIn
  • Follow Us on Twitter
  • Like Us!

© 2017 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top